Dexcom DXCM · USD
Health Care · Health Care Equipment & Supplies · US listing · 🇺🇸 United States
S&P 500Nasdaq-100
81.07
+2.09%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Dexcom
From its filings with the US Securities and Exchange Commission
Dexcom is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker DXCM. It is a member of the S&P 500 and Nasdaq-100. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $4.66bn and net income of $836.3m. At that date it held total assets of $6.34bn and shareholders' equity of $2.75bn. By region, United States accounted for 71.5%, followed by International at 28.5%.
We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians around the world.
We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation systems, the Dexcom G7 Continuous Glucose Monitoring System, or G7, in 2023, and the Dexcom G7 15 Day Continuous Glucose Monitoring System, or G7 15 Day, in late 2025. In August 2024, we launched Stelo, our biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin, as the first over-the-counter glucose biosensor in the U.S.
In March 2022, we obtained Conformité Européenne Marking, or CE Mark, approval for G7. In December 2022, we obtained marketing authorization from the FDA for the G7 via the 510(k) review process. The G7 is an integrated continuous glucose monitoring system, or iCGM, and is classified as a Class II device by the FDA, and is subject to special controls for iCGMs that outline requirements for assuring CGM accuracy, reliability and clinical relevance, and which also outlines the type of studies and data required to demonstrate acceptable CGM performance.
Quoted from its 10-K, filed 12 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 14 Apr 2005
- Employees
- 11,000
- Website
- dexcom.com ↗
- Head office
- 6340 SEQUENCE DRIVE, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Mark FolettaInterim Independent Chairman of the Board$388,066
- Mr. Jacob LeachPresident, Interim Principal Executive Officer, Chief Operating Officer$5.9m
- Mr. Jereme SylvainChief Financial Officer, Executive Vice President$5.9m
- Ms. Sadie SternChief Human Resources Officer, Executive Vice President$4.9m
- Mr. Michael BrownExecutive Vice President, Chief Legal Officer$5.0m
- Mr. Steven AltmanIndependent Director$341,075
- Mr. Nicholas AugustinosIndependent Director$341,728
- Mr. Richard CollinsIndependent Director$343,555
- Ms. Rimma DriscollIndependent Director$343,555
- Ms. Renee GalaIndependent Director
- Ms. Bridgette HellerIndependent Director$341,728
- Mr. Kyle MaladyIndependent Director$341,075
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 66
- Environment
- 50
- Social
- 72
- Governance
- 76
- Direct emissions (scope 1)
- 8,328 t
- Energy emissions (scope 2)
- 36,195 t
- Value chain emissions (scope 3)
- 551,767 t
- Women in the workforce
- 49.51456%
- Carbon reduction policy
- No
- Human rights policy
- Yes
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.